HIV-infected patients receiving office-based treatment are more likely to achieve HIV viral suppression, decreasing the overall community viral load and associated HIV incidence.  Injection Drug Users are least likely to engage in HIV care and achieve HIV viral suppression compared to other HIV risk groups.  Substance abuse treatment can increase engagement in HIV care, but HIV providers have limited options for long-acting office-based addiction treatments.  This study will compare extended-release naltrexone to treatment as usual for opioid dependence in HIV-infected patients. 

CTN Protocol ID: 
CTN-0055
Enrollment Status: 
Completed
ClinicalTrials.gov ID: 

Principal Investigator(s): 

Todd Korthuis, M.D., M.P.H.
Associate Professor of Medicine
Oregon Health & Science University
Department of Public Health & Preventive Medicine
3181 Southwest Sam Jackson Park Road, L475
Portland, OR 97239-3098
korthuis@ohsu.edu

Participating Sites

-->